Genxone (WAR:GX1) Equity-to-Asset : 0.97 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Genxone Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Genxone's Total Stockholders Equity for the quarter that ended in Mar. 2024 was zł14.10 Mil. Genxone's Total Assets for the quarter that ended in Mar. 2024 was zł14.56 Mil. Therefore, Genxone's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.97.

The historical rank and industry rank for Genxone's Equity-to-Asset or its related term are showing as below:

WAR:GX1' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36 Med: 0.87 Max: 0.97
Current: 0.97

During the past 6 years, the highest Equity to Asset Ratio of Genxone was 0.97. The lowest was 0.36. And the median was 0.87.

WAR:GX1's Equity-to-Asset is ranked better than
98.07% of 1558 companies
in the Biotechnology industry
Industry Median: 0.67 vs WAR:GX1: 0.97

Genxone Equity-to-Asset Historical Data

The historical data trend for Genxone's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genxone Equity-to-Asset Chart

Genxone Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

0.54

0.84

0.86

0.95

0.97

Genxone Quarterly Data
	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Equity-to-Asset	Get a 7-Day Free Trial															0.96	0.96	0.96	0.97	0.97

Competitive Comparison of Genxone's Equity-to-Asset

For the Biotechnology subindustry, Genxone's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genxone's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genxone's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Genxone's Equity-to-Asset falls into.

Genxone Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Genxone's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	14.97	/	15.502
	=	0.97

Genxone's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	14.1	/	14.558
	=	0.97

Genxone (WAR:GX1) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Genxone Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Genxone's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Genxone (WAR:GX1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genxone SA (WAR:GX1) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

ul. Kobaltowa 6, Zlotniki, Suchy Las, POL, 62-002

Website

https://www.genxone.eu

Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.

Genxone (WAR:GX1) Headlines

No Headlines